Dr. Alex Matter       CML          Chronic  Myeloid Leukemia

''Dr. Alex Matter is best known for his contribution to the development of
Glivec/Gleevec, one of the world’s first tyrosine kinase inhibitor drugs against
chronic myeloid leukemia (CML). Starting in the mid-eighties, Dr. Matter led a
team of close to 200 scientists at Novartis to discover and optimize the lead
compound and brought it all the way through its first clinical trial in 1998. In
a short span of 3 years, Glivec/Gleevec was given a very rare, fast track FDA
approval in 2001.''
Extract of CV of  Alex Matter

"Father of targeted therapies" receives top  U.S. award
 April 6, 2013, English.news.cn
 
Dr. Alex Matter has been awarded the 8th  Annual Szent-Gyorgyi  Prize for Progress in Cancer Research
January 29, 2013, National Foundation for Cancer  research

Executive Summary of a Book: Magic  Cancer Bullet
May 23, 2009, Discovery  Medecine


                                           See also History of CML